

FAX



GlaxoSmithKline

30
IDS

To Examiner Jimmy G. Foster, Group 3728
Company USPTO
Fax 703-872-5502 *308-7769*
From Marjorie J. Pfeiffer
Tel 1-919-483-9038; Facsimile: 1-919-483-7988
E-mail Mjp14849@gsk.com
Date September 15, 2003 **Pages including cover** 5
Subject Information Disclosure Statement

Tel: 919 483 2100

RECEIVED

*GROUP 3200
RECEIVED
Sep. 15, 2003 JF
GROUP 3200
GROUP 3720*

Re: Application of Karl Andrew GARRILL et al.
U.S. Serial No.: 09/599,274; Filed: June 22, 2000
Title: *Method and Package for Storing a
Pressurized Container Containing a Drug*
Attorney Docket No. PG4114

Attached:

1. Information Disclosure Statement with Certificate of Transmission by Facsimile (37 CFR 1.8) and form PTO-1449

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Karl Andrew GARRILL et al.

Serial No.: 09/599,274

Art Unit: 3728

Filing Date: June 22, 2000

Examiner: Jimmy G. Foster

For: *Method and Package for Storing
a Pressurized Container
Containing a Drug*Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Copies of the references are enclosed.
 Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
 A copy of the International Search Report which issued on International Application No. ____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted or deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: September 15, 2003
Marjorie J. Pfeiffer

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):


Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]

Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

Please charge any required fees to Deposit Account No.07-1392.
 A duplicate copy of this paper is attached.

Respectfully Submitted,



Attorney of Record: Robert J. Smith
Registration No. 40,820

Date: September 15, 2003
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-9616
Facsimile: (919) 483-7988